Bioactive compounds from Streptomyces nasri and its mutants with special reference to proteopolysaccharides

• Autorzy: Gohar Y , Beshay U. , Daba A. , Hafez E.
• Języki publikacji: EN

Abstrakty

EN

The use of microbial exopolysaccharides (EPS) in the food, pharmaceutical, and chemical industries has steadily increased during the past decade. A bioactive EPS producing microorganism, Streptomyces nasri was isolated from Kuwait tropical soil and the proteopolysaccharide was tested for its antimicrobial activity. The isolate was subjected to ultraviolet (UV) radiation and acridine orange (AO) treatment to select for superior proteopolysaccharide producers. Among eight (five derived from UV exposure and three from AO exposure) morphological variants of Streptomyces nasri, two mutants showed increased EPS production, from 1.8 g/l to 2.3 g/l. The SDS-PAGE profiles of exopolysaccharides were determined. The molecular weight of the proteopolysaccharide ranged from 18 to 200 kDa. Mutants derived from UV exposure produced polysaccharides with higher molecular weight than those derived from acridine orange exposure. Acridine orange derived mutants produced lower molecular weight polysaccharides. Culture super-natants have been partially characterized and they show antimicrobial activity against a wide range of microorganisms. The structure of the exopolysaccharide was determined using NMR spectroscopy. The polysaccharide was also tested for cytotoxic activity against human brain tumor cell line using SRB assay.

Słowa kluczowe

EN

polysaccharide; Streptomyces; mutation; bioactive compound; microbiology; antimicrobial activity; microbial polysaccharide

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2006
• Tom: 55
• Numer: 3
• Opis fizyczny: p.179-187,fig.,ref.

Twórcy

autor

Gohar Y

• Alexandria University, Alexandria, Egypt

autor

Beshay U.

autor

Daba A.

autor

Hafez E.

Bibliografia

• Adachi Y., N. Ohno, M. Ohsawa, S. Oikawa and T. Yadomae. 1990. Change of biological activities of (1-3)-β-D-glucan from Grifola frondosa upon molecular weight reduction by heat treatment. Chem. Pharm. Bull. 38: 477-481.
• Amade P., M. Mailea and N. Bouaicha. 1994. Isolation, structural identification and biological activity of two metabolites produced by Penicillium olsonii Bainier and Sartory. J. Antibiot. 47: 201-207.
• Babineau T.J., A. Hackford, A. Kenler, B. Bistrian, R.A. Forse, P.G. Fairchild, S. Heard, M. Kerorack, P. Causha and P. Benotti. 1994a. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch. Surg. 129: 1204-1210.
• Babineau T.J., P. Marcello, W. Swails, A. Kenler, B. Bistrian and R.A. Forse. 1994b. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann. Surg. 220: 601-609.
• Browder W., D. Williams, H. Pretus, G. Olivero, F. Enrichens, P. Mao and A. Franchello. 1990. Beneficial effect of enhanced macrophage function in the trauma patient. Ann. Surg. 211: 605-613.
• Chihara G., YY Maeda, J. Hamuro, T. Shiio, T. Suga, N. Takasuka and T. Sasaki. 1987. Antitumour and metastasis-inhibitory activities of lentinan as immunomodulator: An overview. Cancer Detect. Prev. 1: 423-442.
• Chihara G., Y.Y. Maeda, T. Suga and J. Hamuro. 1989. Lentinan as a host defense potetiator (HDP). Int. J. Immunother. 4: 145-150.
• Dela Cruz N., G.F. Payne, J.M. Smith and S.J. Coppella. 1992. Bioprocess development to improve foreign protein production from recombinant Streptomyces. Biotechnol. Prog. 8: 307-315.
• Franz G. 1989. Polysaccharides in pharmacy: Current applications and future concepts. Planta Med. 55: 493-497.
• Grabley S. and R. Thiericke. 1999. Drug Discovery from Nature, Chapter 7: Secondary metabolites-from past to present, Springer-Verlag Berlin Heidelberg, New York. 117-123.
• Hamano K., H. Gohra, T. Katoh, Y. Fujimura, N. Zempo and K. Esato. 1999. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. Int. J. Immunopharmacol. 21: 531-540.
• Hashem M.A. and A. Diab. 1973. Some physiological studies on Streptomyces nasri sp. nov. from the desert of Kuwait. Zentralbl. Bakteriol. Parasit. Abstrakt. 128: 356-362.
• Held T. and H.J. Kutzner. 1991. Genetic recombination in Streptomyces michiganensis DSM 40015 revealed three genes responsible for the formation of melanin. J. Basic Microbiol. 31: 127-134.
• Itoh W., I. Sugawara, S. Kimura, K. Tabata, A. Hirata, T. Kojima, S. Mori and K. Shimada. 1990. Immunopharmacological study of sulfated schizophyllan (SPG) I. Its action as a mitogen and anti-HIV agent. Int. J. Immunopharmacol. 12: 225-233.
• Kimura Y, H. Tojima, S. Fukase and K. Takeda. 1994. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol. Suppl. 511: 175-178.
• Laemmli U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
• Mizuno T., P. Yeohlui, T. Kinoshita, C. Zhuang and Y. Moyuzumi. 1996. Antitumour activity and chemical modification of polysaccharides from niohshimeji mushroom, Tricholoma giganteum. Biosci. Biotechnol. Biochem. 60: 30-33.
• Nakano T, K. Oka, K. Hanba and S. Morita. 1996. Intratumoral administration of sizofilan activates Langerhan cell and T-cell infiltration in cervical cancer. Clin. Immunol. Immunopathol. 79: 79-86.
• Ohno N., M. Furukawa, N. Miura, Y. Asachi, M. Motoi and T. Yadomae. 2001. Antitumour β-glucan from the cultured fruit body of Agaricus blazei. Biol. Pharm. Bull. 24: 820-828.
• Ooi V.E. and F. Liu. 2000. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr. Med. Chem. 7: 715-729.
• Ross G.D., V. Vetvicka, J. Yan, Y. Xia and J. Vetvickova. 1999. Therapeutic intervention with complement and β-glucan in cancer. Immunopharmacology 42: 61-74.
• Sacramento D.R., R.R. Rodrigues, M.D. Wigg, L.F. Linhares, M.G. Santos, L.T. Semado and A.J. Silva. 2004. Antimicrobial and antiviral activities of an actinomycete (Streptomyces sp.) isolated from Brazilian tropical forest soil. World J. Microbiol. Biotechnol. 20: 225-229.
• Sanglier J.J., E.M. Wellington, V. Behal, H.P. Fiedler, R. Ellouz Ghorbel, C. Finance, M. Hacene, A. Kamoum, C. Kelly, D.K. Mercer, S. Prinzis and C. Trigo. 1993. Novel bioactive compounds from actino-mycetes. Res. Microbiol. 144: 661-663.
• Skehan P., R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney and M.R. Boyd. 1990. New colorimetric cytotoxicity assay for anti-cancer drug screening. J. Natl. Cancer Inst. 82: 1107-1112.
• Sutherland I.W. 1990. Biotechnology of Microbial Exopolysaccharides. Cambridge University Press. Cambridge
• Sutherland I.W. 1998. Novel and applied application of polysaccharide. Trends Biotechnol. 16: 41-46.
• Sutherland I.W. 2001. Microbial polysaccharides from Gram-negative bacteria. Int. Dairy J. 11: 663-674.
• van Geel-Schutten G.H., F. Flesch, B. Brink, M.R. Smith and L. Dijkhuizen. 1998. Screening and characterization of Lactobacillus strains producing large amounts of exopolysaccharides. Appl. Microbiol. Biotechnol. 50: 697-703.
• Venkateswarlu G., P.S. Murali Krishna, G. Sharma and L.V. Rao. 2000. Improvement of rifamycin B production using mutant strains of Amycolatopsis mediterranei. Bioprocess Eng. 23: 315-318.
• Vetvicka V. 2001. β-glucans as immunomodulators. The Journal of the American Nutraceutical Association (JANA) 3: 24-31
• Zhang Y, H. Li and W. Lu. 1993. Taxonomic study on strain 1254 and its mutant 113. Acta Microbiol. Sin. 33: 13-21.